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Abstract
Probenecid has been widely used in the treatment of gout, but evidence suggest that it
may also have anti-nociceptive effects in different inflammatory and pain conditions.  We
examined the potential modulatory effects of probenecid on behavioural and morphological
markers in the orofacial formalin test of the rat. 
One  hour  after  pre-treatment  with  vehicle  or  probenecid  (1  mmol/kg  body  weight)
intraperitoneally,  50µl  1.5%  formalin  solution  or  physiological  saline  was  injected
subcutaneously  into  the  right  whisker  pad of  rats.  The  rubbing  activity  directed  to  the
injected whisker pad was then measured for a period of 45 minutes. Four hours after formalin
injection, the caudal part of spinal trigeminal nucleus was removed and subjected to c-Fos
and neuronal nitric oxide synthase (nNOS) immunohistochemistry and to interleukin-1β
and NAD(P)H:quinone oxidoreductase 1 (NQO1) Western blot. 
There was a significant decrease in formalin-induced biphasic behavioural response
and  c-Fos  and  nNOS  immunoreactivity  in  the  rats  who  were  pre-treated  with
probenecid. However there were no alterations in expression of interleukin-1β or NQO1
after formalin administration. 
Our  results  suggest  that  probenecid  has  an  anti-nociceptive  effect  in  the trigeminal
inflammatory  pain  model.  This  effect  may  be  through  influencing  the  release  of
prostaglandin E2 or desensitizing the transient receptor potential channel subtype A
member 1 or the transient receptor potential channel subtype V member 2 or the effect
may be through modulating kynurenic acid levels in the central nervous system. Thus,
probenecid might be a potential candidate for the treatment of trigeminal activation related
pain conditions. 
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 Introduction
Probenecid  (PROB,  p-(di-n-propylsulfamyl)benzoic  acid)  has  primarily  been  used  to
enhance the renal retention of penicillin  and to treat gout, due to its ability to increase the
renal excretion of uric acid . Besides its effects on the kidney,  research data suggest that
PROB  may  have  anti-inflammatory  and  anti-nociceptive  properties  as  well. PROB
blocks the multidrug resistance-associated protein 4 (MRP4), an organic anion transporter ,
which is crucial in the release of key inflammatory mediators such as prostaglandin E1 and
prostaglandin E2 (PGE2) . In addition, PROB inhibits the pannexin-1 channel , which may be
relevant in neuronal inflammatory processes . On the other hand, PROB is an agonist of the
transient receptor potential channel subtype A member 1 (TRPA1)  and the transient receptor
potential channel subtype V member 2 (TRPV2)  , which play an important role in pain
sensation  .  It  is  also  well  known,  that  an  agonist-mediated  desensitization  of  these
TRPA1 and TRPV2 can be induced , leading to analgesia. These results strongly suggest
that PROB might be effective in mitigating inflammation and nociception. In contrast,
Bang and co-workers raise the possibility  that PROB can elicit  the pain induced by
inflammation through its agonism on TRPV2 . 
Fundamental  research  and  pharmacological  studies  investigating  the  trigeminal
inflammation and nociception often use the orofacial formalin test, a reliable model for
studying somatic pain causing the activation and sensitization of trigeminal system ,
which is crucial in the pathomechanism of headaches such as migraine  - one of the most
common neurological  disorders .  Formalin  solution  administered  subcutaneously into the
upper lip gives rise to a tissue injury, nociception and inflammation , activating the primary
nociceptors, enhancing the immunoreactivity of c-Fos, a marker of neuronal activation  in the
caudal part of spinal trigeminal nucleus (TNC)  and resulting  in an increase in neuronal
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nitric oxide synthase (nNOS), which is a suggested marker of central sensitization . The
induction of formalin causes a biphasic nociceptive behavioural response consisting of
rubbing acitivity  during an early  and short-lasting  (3–4 min)  first  phase  of  rubbing is
followed by a tonic prolonged (20–22 min) second phase, the phases being separated by a 9–
10  min  quiescent  period  .  The  first  phase  is  thought  to  be  due  to  the  direct  chemical
stimulation  of  the  nociceptors  by  the  formalin  solution,  while  the  second  phase  is  a
manifestation of the processes induced in the spinal cord during the first phase, together
with  peripheral  inflammation  .  The  inflammatory  mediators  such  as  PGE2  and
interleukin-1β  (IL-1  β)  and  the  oxidative  stress  may  have  important  role  in  the
formation of changes induced by subcutaneous (s.c.) formalin injection . 
Based on previous experimental results, it has been proposed that PROB, through its
different receptorial actions, may have anti-nociceptive effect that can be seen in the
orofacial formalin test. Thus the aim of the current study was to investigate whether PROB
exerts  a modulatory effect in this tonic trigeminal pain model through the examination of
behavioural and morphological markers. 
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 Materials and Methods 
1. Animals:
The procedures used in this study followed the guidelines of the eighth edition of the Guide
for the Care and Use of Laboratory Animals and the Use of Animals in Research of the
International Association for the Study of Pain and the directive of the European Economic
Community (86/609/ECC). They were approved by the Committee of Animal Research at the
University  of  Szeged  (I-74-12/2012)  and  the  Scientific  Ethics  Committee  for  Animal
Research of the Protection of Animals Advisory Board (XXIV./352/2012.). Sixty adult male
Sprague-Dawley rats weighing 200-250 g were used. The animals were raised and housed
under  standard  laboratory  conditions  (in  an  air-conditioned,  humidity-controlled  and
ventilated room), with drinking water and regular rat chow available ad libitum on a 12h-12h
dark-light cycle. Each rat was used only once.
2. Drug administration:
The rats were divided into two groups (n=30 per group). The animals in the Placebo group
received only intraperitoneal vehicle solution (physiological saline, 1.5 ml) as pre-treatment.
In  the  PROB group,  the  rats  were  pretreated  with  an  intraperitoneal  injection  of  PROB
(Sigma-Aldrich; 1 mmol/kg body weight, diluted to 1.5 ml, pH 7.4). Both groups of animals
were divided further  into  two subgroups (n=15):  1  hour after  the PROB or  vehicle  pre-
treatment, half of the animals received a s.c. injection of 50 µl 1.5% formalin solution (0.55%
formaldehyde, Sigma-Aldrich) diluted in physiological saline, administered  via a 26-gauge
needle into the right whisker pad (Placebo-Form and PROB-Form), while the other half of
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the rats were injected with s.c. 50 µl physiological saline without formalin (Placebo-Phys and
PROB-Phys). 
3. Behavioural test:
The testing procedures were performed during the light phase (between 8 a.m. and 2 p.m.)
in a quiet room. The test box was a 30 x 30 x 30 cm glass terrarium with mirrored walls. For
the off-line analysis  of rubbing activity directed to the whisker pad, the behaviour of the
individually tested rats  was recorded with a video camera (Logitech  HD Webcam C615)
situated 1 m above the terrarium.  One hour after pre-treatment with vehicle (n=20) or
PROB (n=20) and after a 10-min habituation in the test box, the whisker pads of the rats
were  injected with s.c. formalin  (n=10 per subgroup) or physiological saline  (n=10 per
subgroup) and the animals were replaced immediately back in the chamber for 45 min. The
rats did not receive any food or water during the observation period. The test box was cleaned
and decontaminated  after  each animal.  An observer  blind to  the experimental  procedures
analysed the recorded videos. The 45-min recording period was divided into 15x3-min blocks
and the total time (number of seconds) spent on rubbing the injected area with the ipsilateral
fore- or hindpaw was measured in each block and defined as the nociceptive score for that
block. Earlier literature findings led us to use the grooming activity as control, measured in
animals that received s.c. physiological saline . 
4. c-Fos and nNOS immunohistochemistry:
Four  hours after  the  formalin  or  physiological  saline injection,  the  rats  (n=5-9  per
subgroup) were  perfused  transcardially  with  100  ml  phosphate-buffered  saline  (PBS),
followed by 500 ml 4% paraformaldehyde (Merck) in phosphate buffer under deep chloral
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hydrate  (0.4  g/kg  body  weight,  Sigma-Aldrich)  anaesthesia.  The  medullary  segment
containing the TNC between +1 and -5 mm from the obex was removed, postfixed overnight
for immunohistochemistry in the same fixative and cryoprotected (10% sucrose for 2 h, 20%
sucrose until the blocks sank, and 30% sucrose overnight). Before sectioning, each segment
was marked with a small  incision on the ventral and left  (contralateral)  side of the tissue
block,  allowing  side  discrimination  during  the  quantification  process.  30-μm  transverse
cryostat sections were cut through the rostrocaudal axis from the beginning of the TNC and
were serially  collected  in  wells  containing  cold  PBS.  Each  well  contained  every  tenth
section at 0.3-mm intervals along the rostrocaudal axis (15 levels/sections). The free-floating
sections were rinsed in PBS and immersed in 0.3% H2O2 (Scharlau Chemie) in PBS for 30
min to suppress endogenous peroxidase activity. After several rinses in PBS containing 1%
Triton  X-100  (PBST;  VWR International),  sections  were  incubated  at  room temperature
overnight  in  PBST  containing  rabbit  anti-rat  c-Fos  polyclonal  antibody  (Santa  Cruz
Biotechnology, sc-52) at a dilution of 1:2000 or at 4°C for two nights in PBST containing
rabbit  anti-rat  nNOS  polyclonal  antibody  (EuroProxima,  B220-1)  at  a  dilution  of
1:5,000. The immunohistochemical reaction was visualized by using Vectastain Elite avidin-
biotin  kits  (Vector  Laboratories,  PK6101).  Briefly,  the  sections  were  incubated  at  room
temperature for 2 hours in PBST containing goat anti-rabbit biotinylated secondary antibody.
After  several  rinses  in  PBST,  and incubation  at  room temperature  for  2  hours in  PBST
containing  avidin  and biotinylated  horseradish peroxidase,  the sections  were stained with
3,3’-diaminobenzidine (Sigma-Aldrich) intensified with nickel ammonium sulphate (Scharlau
Chemie).  The  specificity  of  the  immune  reactions  was  checked  by omitting  the  primary
antiserum.
The counting of immunoreactive (IR) cells in the TNC was performed by an observer blind
to  the  experimental  procedures  under  the  10x  objective  of  a  Nikon  Optiphot-2  light
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microscope in every tenth transverse section in each animal. Before the counting,  the
location of each section along the rostrocaudal axis and the location of the TNC on each
medullary section were determined by means of The Rat Brain in Stereotaxic Coordinates
Atlas  .  The c-Fos neurones with obvious specific  nuclear  staining and the nNOS-IR
neurones  with  cytoplasmic  and  dendritic  staining  and  a  nucleus  were  taken  into
consideration and were counted in  the TNC both ipsilaterally  and contralaterally  to the
formalin or physiological saline injection. 
5. IL-1β and NAD(P)H:quinone oxidoreductase 1 (NQO1) Western blot:
Four  hours  after  the  formalin  or  physiological  saline  injection,  the  rats  (n=5  per
subgroup) were deeply anaesthetized with chloral hydrate as described above, perfused
transcardially with 100 ml ice cold PBS and the ipsi- and contralateral side of the TNC
between 0 and -4 mm from the obex was removed. Until measurements, the samples
were  stored  at  −80°C.  The  TNC  segments  were  sonicated  in  ice  cold  lysis  buffer
containing 50 mM Tris-HCl,  150 mM NaCl,  0.1% igepal,  0.1% cholic  acid,  2 μg/ml
leupeptin,  2  mM phenylmethylsulphonyl  fluoride  (PMSF),  1  μg/ml pepstatin,  2  mM
EDTA  and  0.1%  sodium  dodecyl  sulphate  (SDS)  (all  chemicals  were  from  Sigma-
Aldrich). The lysates were cleared from cellular debris by centrifugation at 12,000 RPM
for  10  min  at  4°C  and  supernatants  were  aliquoted  and  stored  at  -20°C.  Protein
concentration was measured according to BCA protein assay method with BCA Protein
Assay Kit (Novagen) using bovine serum albumin as a standard. Samples were cooled
on ice  during the  whole procedure.  Prior  to loading into the  gels,  each sample was
mixed with sample buffer, and denaturated by boiling for 3 min. Equal amounts of
protein  samples  (20  μg/lane)  were  separated  by  standard  SDS  polyacrylamide  gel
electrophoresis  (SDS-PAGE)  on  12%  Tris–Glycine  gel  and  electrotransferred  onto
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Amersham Hybond-ECL nitrocellulose membrane (0.45 μm pore size, GE Healthcare).
The  Page  Ruler  Prestained  Protein  Ladder  (Fermentas,  10-170  kDa)  was  used  to
determine approximate  molecular  weights.  Following the  transfer,  membranes  were
blocked for one hour at room temperature in Tris-buffered saline containing Tween 20
(TBST, MP Biomedicals) and 5% non fat dry milk powder and then incubated in TBST
containing  1%  non  fat  dry  milk  and  (i)  rabbit  anti-rat  IL-1β  (H-153)  polyclonal
antibody (Santa Cruz Biotechnology, sc-7884, dilution: 1:200, incubation: overnight at
4°C)  or  (ii)  rabbit  anti-rat  NQO1  (H-90)  polyclonal  antibody  (Santa  Cruz
Biotechnology, sc-25591, dilution: 1:200, incubation: overnight at 4°C) or (iii)  mouse
anti-rat  β-actin  monoclonal  antibody  (Calbiochem,  CP01,  dilution:  1:100,000,
incubation: overnight at 4°C). Next day after several rinses in TBST, membranes were
incubated  in  TBST  containing  1%  non  fat  dry  milk  and  horseradish  peroxidase-
conjugated anti-rabbit or anti-mouse secondary antibody (Santa Cruz Biotechnology;
sc-2030 and sc-2031) for 2 hours at room temperature. Protein bands were visualized
after  incubation  of  membranes  with  the  SuperSignal  West  Pico  Chemiluminescent
Substrate (Pierce) using Carestream Kodak BioMax Light film (Kodak). 
For densitometric  analyses,  films were  scanned and quantified using Java ImageJ
1.47v analysis software (National Institutes of Health). The β-actin was used as sample
loading control and normalization protein as well. The results from each animal were
further normalized to its own contralateral side. 
6. Statistical analysis:
In the behavioural study, comparisons were made of the rubbing activity in each block of 3-
min in each of the subgroups (Placebo-Form, Placebo-Phys, PROB-Form and PROB-Phys)
by using two-way repeated measures ANOVA. Subgroups were used as the between-subject
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factor and 15 blocks of 3-min as the within-subject factor for the analysis. When Mauchly’s
test  of  sphericity  proved  significant,  the  Greenhouse-Geisser  correction  was  performed.
Pairwise comparisons of subgroup means were based on the estimated marginal means with
Sidak adjustment for multiple comparisons.
To compare statistical differences between subgroups in the first and second phases, the
two phases  were  determined  on the  basis  of  significant  results  detected  during  two-way
repeated measures ANOVA described above. The first phase was found to be the first of the
15  blocks,  while  the  second phase  was  the  sum of  the  fifth  to  the  eleventh  blocks.  To
determine significant differences between subgroups in the first or second phase, we used
one-way ANOVA followed by the Tamhane post hoc test. 
In terms of the immunoreactivity,  the numbers of IR neurones in the various subgroups
(Placebo-Form, Placebo-Phys, PROB-Form and PROB-Phys) were compared at each level of
0.3-mm  (15  levels)  along  the  rostrocaudal  axis  by  using  two-way  repeated  measures
ANOVA. Since there was no significant difference in the number of c-Fos-  and nNOS-IR
neurones between the contralateral sides in the subgroups injected with s.c. formalin and the
contra- and ipsilateral sides in the subgroups injected with s.c. physiological saline (data not
shown), in the course of the statistical analysis the data obtained from the contralateral sides
of the subgroups injected with s.c. formalin were used as controls. The contra- and ipsilateral
sides of the formalin-injected subgroups were used as the between-subject factor, and the 15
levels  along  the  rostrocaudal  axis  as  the  within-subject  factor  for  the  analysis.  When
Mauchly’s  test  of  sphericity  proved  significant,  the  Greenhouse-Geisser  correction  was
performed. Pairwise comparisons of subgroup means were based on the estimated marginal
means with Sidak adjustment for multiple comparisons. 
Statistical analysis of the Western blot data was carried out using one-way ANOVA
followed by the Sidak  post hoc test. Since there was no significant difference in band
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densities between the contralateral sides in the subgroups injected with s.c. formalin
and the contra- and ipsilateral sides in the subgroups injected with s.c. physiological
saline (data not shown), in the course of the statistical analysis the data obtained from
the contralateral sides of the subgroups injected with formalin were used as controls.
All tests were two-sided, and probability levels p<0.05 were considered to be statistically
significant. Group values are reported as means ± S.E.M.
Statistical analysis of measurements was carried out with IBM SPSS Statistics, version 20
(IBM Corporation) software. 
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Results
1. Nociceptive response
The  behavioural pattern observed in the rats is in accordance with previous findings .
After the formalin injection, the rats immediately withdrew their heads, often accompanied
by vocalization. Following their return to the observation box, the rats started to rub their
whisker pad continuously and intensely with the ipsilateral forepaw accompanied often by
the contralateral  forepaw, and occasionally scraped the perinasal  area with the ipsilateral
hindpaw after a period of ~20 sec. This period, referred to as the first phase, lasted ~3-4 min,
and was followed by a quiescent  period of 9-10 min,  separating the first  phase from the
second phase. The second phase was characterized by less intense, but continuous rubbing of
the face,  predominantly with the ipsilateral  forepaw  consorted often  by the contralateral
forepaw as  well.  This  tonic  phase  lasted  ~20-22 min.  In  the  PROB-Form subgroup,  the
behavioural pattern in both phases was clearly less pronounced than that in the Placebo-Form
subgroup, and such behaviour was not witnessed at all in the Placebo-Phys and PROB-Phys
subgroups, where the animals displayed very little rubbing/grooming activity. 
The comparison of the 3-min blocks revealed significant  differences in rubbing activity
between the Placebo-Form and Placebo-Phys subgroups in the first (***p < 0.001) and fifth
to eleventh (**p < 0.01; ***p < 0.001) blocks (Fig. 1). The PROB pre-treatment significantly
decreased  the  formalin-induced  nociceptive  behaviour  in  each  block  (# #p < 0.01;
# # #p < 0.001; Fig. 1). However, it should be noted that PROB did not attenuate the effect of
formalin completely in the first block, where the time spent on rubbing was still significantly
higher than that in the Placebo-Phys subgroup (*p < 0.05; Fig. 1). There was no significant
difference between the Placebo-Phys and PROB-Phys animals in any block, nor was between
the PROB-Form and PROB-Phys subgroups in any other block apart from the first (Fig. 1). 
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The face rubbing activity in the Placebo-Form subgroup was significantly higher during
both the first (***p < 0.001) and the second phase (***p < 0.001) than that in the Placebo-
Phys subgroup (Fig.  2).  PROB significantly decreased  the nociceptive  behaviour  in both
phases (**p < 0.01; ***p < 0.001; Fig. 2), however this effect was not complete in the first
phase (*p < 0.05; Fig. 2). 
2. c-Fos in the TNC
Microscopic examination of the immunostained transverse sections of the TNC revealed
c-Fos  immunoreactivity  in  the  nuclei  of  the  neurones.  In  the  Placebo-Form  subgroup,
unilateral s.c. formalin injection produced an increase in the number of c-Fos-IR neurones in
the dorsal, superficial area  of the transverse sections of the ipsilateral TNC as compared
with the non-treated contralateral side (Fig. 3/A). This increase was significant at different
levels  along  the  rostrocaudal  axis  (between  -0.3  and  -3.3  mm),  in  accordance  with  the
somatotopic representation (**p < 0.01; ***p < 0.001; Fig. 3/C). 
In  the PROB-Form subgroup,  the number  of c-Fos-IR neurones at  the different  levels
along the rostrocaudal axis also increased in the ipsilateral TNC. This effect was similar, but
less pronounced than that in the Placebo-Form subgroup (Fig. 3/B), i.e. PROB significantly
decreased the formalin-related activation of the second order trigeminal neurones at several
levels of the TNC (between -0.3 and -2.4 mm; #p < 0.05; # #p < 0.01; # # #p < 0.001; Fig. 3/C).
On the contralateral sides of the TNCs, there were no significant differences either between
the subgroups or between the different levels along the rostrocaudal axis (Fig. 3). 
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3. nNOS in the TNC
On  the  immunostained  transverse  sections,  the  nNOS-IR  neurones  showed
cytoplasmic and dendritic staining. The unilateral s.c. formalin injection gave rise to an
increase  in  the  number of  nNOS-IR neurones  in  the  dorsal,  superficial  area of  the
ipsilateral  TNC compared to the non-treated contralateral  side in the Placebo-Form
subgroup (Fig. 4/A). Along the rostrocaudal axis, significant increase can be observed at
different  levels  (between  -2.1  and  -2.7  and  between  -3.3  and  -3.9  mm;  *p < 0.05;
**p < 0.01;  Fig.  4/C).  In  the  PROB-Form subgroup,  there  was no difference  in  the
number of nNOS-IR neurones between ipsilateral and contralateral TNC (Fig. 4/B), i.e.
PROB significantly  decreased  the  number  of  the  second  order  trigeminal  neurones
expressing nNOS at several levels of the TNC (between -2.1 and -2.7 and between -3.3
and -3.9 mm; #p < 0.05;  # #p < 0.01; Fig. 4/C) at the injected side. On the contralateral
sides of the TNCs, there were no significant differences either between the subgroups or
between the different levels along the rostrocaudal axis (Fig. 4). 
4. IL-1β and NQO1 in the TNC
The Western blot analysis of the TNC segments did not show significant difference
between the contra- and ipsilateral sides for any of the subgroups either in the case of
IL-1β or in the case of  NQO1 (data not shown),  which means that IL-1β or NQO1
expression did not change four hours after the unilateral  s.c.  formalin injection and
PROB pre-treatment did not have any modulatory effect on the expression of IL-1β or
of NQO1. 
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Discussion 
This is the first study showing that PROB produced a pronounced anti-nociceptive
behavioural effect in the orofacial formalin test especially in the second phase. PROB
exhibited no effect on the baseline activity of the control animals, which received a s.c. saline
injection in the whisker pad. In addition to the modulation of the nociceptive behaviour,
PROB also mitigated the formalin induced c-Fos and nNOS expression in the TNC –
considered markers of activation and sensitization of these neurones . 
This anti-nociceptive effect of PROB along with its inhibitory effect on the trigeminal
activation and sensitization can be the result of various mechanisms: 
PROB inhibits  MRP4,  an  organic  anion  transporter  ,  which  releases  key inflammatory
mediators  such as prostaglandin  E1 and PGE2 from cells  in  a  time- and ATP-dependent
manner , and these mediators contribute to inflammation and hyperalgesia . PGE2 released
from cultured rat trigeminal ganglion nerve cells  can sensitize transient receptor potential
channel subtype V member 1 (TRPV1)  (a key factor in the development of sensitization
during nociception ). Moreover, PGE2 can induce calcitonin gene-related peptide (CGRP)
release (a general event after the activation of first order trigeminal neurones ) from cultured
trigeminal ganglion cells . PGE2 can also act on the trigeminal system at the level of the
central  nervous  system  by  enhancing  the  capsaicin-induced  CGRP  release  in  slice
preparations of the TNC  . The expression of cyclooxygenase-2 (an inducible enzyme of
prostaglandin  synthesis  )  has  also  been  detected  in  the  neurones  and  glial  cells  in  the
trigeminal ganglion  and in the neurones of the TNC . In addition, prostaglandin receptors
play  a  relevant  role  in  trigeminal  nociception  and  in  the  pathomechanism of  trigeminal
activation . They are present in the trigeminal ganglion , co-expressed with TRPV1, with a
functional interaction between them in the trigeminal system , and are involved in mediating
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CGRP  release  from  cultured  rat  trigeminal  neurones  .  Quantitative  autoradiography  has
revealed that TNC has a moderate density of PGE2 binding sites  as well, and the mRNA of
all  prostaglandin receptors  are also present there .  Accordingly,  a possible mechanism of
action  of  PROB  is  the  inhibition  of  the  release  of  PGE2,  a  key  player  in  trigeminal
nociception and an important molecule in migraine genesis  through the blockade of MRP4. 
PROB also inhibits the pannexin-1 channel , which may be relevant in inflammation  and
hence in pain processing. The pannexin-1 channels are mainly expressed in the spinal cord ;
moreover,  they  are  present  in  the  postsynaptic  neurones   and  are  crucial  in  caspase-1
activation, which leads to the production and release of interleukin-1beta (IL-1β) in neurones,
astrocytes  and macrophages . The release of IL-1β from trigeminal ganglion satellite cells
may contribute to the mechanisms underlying trigeminal inflammatory hyperalgesia .  Up-
regulation of astrocytic IL-1β in the TNC can lead to central sensitization  via its receptors
present on trigeminal neurones in the same area . The interleukin-1 receptor antagonists were
effective in modulation of changes caused by noxious stimulation  . Consequently, these
results clearly indicate that IL-1β plays a role in trigeminal activation. However the results
of our Western blot measurement showed that there were not changes in the expression
of IL-1β at the level of TNC four hours after s.c. formalin administration and therefore
it is not possible that PROB exerts such effect on this level, but one can not exclude the
possibility that PROB affects IL-1β in the periphery, at the inflammation site or in the
trigeminal ganglion. 
It is important to note that some data suggest that PROB is able to activate  some of the
transient  receptor  potential  channels,  including  TRPV2 and TRPA1  which play  an
important role in pain perception  and are present in the trigeminal system . However, the
agonist-mediated desensitization of these receptors is also known , which can cause an
anti-nociceptive effect .  PROB can desensitize the TRPA1  and may act similarly on
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TRPV2 as well, which might account of its anti-nociceptive properties in the present
experiments. 
It is a well-known fact that PROB can increase the concentration of kynurenic acid -
an  endogenous  tryptophan  metabolite   -  in  the  central  nervous  system  .  This
phenomenon can be  caused by inhibition  of  organic  anion transporters  by PROB ,
which are involved in the transport of kynurenic acid taking place from brain through
the blood-brain barrier  or by increasing of concentration of tryptophan in the central
nervous system . Experimental data suggest that kynurenic acid can affect nociception
and elevation in its concentration in the brain can inhibit the trigeminal activation ,
probably  due  to  an  antagonistic  effect  on  ionotropic  glutamate and  α7-nicotinic
acetylcholine receptors  or due an agonistic action on G-protein-coupled receptor-35 ,
which receptors play important role in pain processing and trigeminal activation . 
Several lines of evidence confirm the role of oxidative stress in the induction of tissue
damage e.g.  neuronal  activation caused by inflammation in orofacial  formalin test  .
However, in the present study, we could not support this hypothesis, since the NQO1
expression,  a marker of  oxidative  stress  ,  remained unchanged four hours after s.c.
formalin injection. 
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Conclusions
The results of our study provide evidence that pre-treatment with PROB can have
anti-nociceptive  effects  and  can  modulate  the  changes  induced  by  trigeminal
inflammation in both behavioural and morphological markers in the rat orofacial formalin
test.  PROB  may exert  this effect through inhibition of the inflammatory processes  which
could  be  through  blocking  the  MRP4,  which  induces  the  release  of  key  inflammatory
mediators  such  as  PGE2  or  through  desensitization  of  TRPA1  and  TRPV2  or  by
enhancing  concentration  of  kynurenic  acid  in  the  brain.  These  properties  and  the
relatively good side effect profile can make PROB a possible pharmacological candidate in
the treatment of trigeminal activation related pain.  
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Figure legends
Fig. 1. Diagram showing the time (number of seconds) spent rubbing the injected area with
the ipsilateral fore- or hindpaw in each block of 3 min in all 4 subgroups. In the Placebo-
Form  subgroup  (black  diamonds),  the  two  phases  of  formalin  action  are  clearly
distinguishable.  The  rubbing  activity  in  the  first  (***p < 0.001)  and  in  the  fifth  to
eleventh (**p < 0.01; ***p < 0.001) blocks was significantly higher in the Placebo-Form
subgroup (black diamonds) than in the Placebo-Phys subgroup (dark-grey squares). The
PROB pre-treatment significantly reduced the formalin-induced nociceptive behaviour in
each  of  the  above-mentioned  blocks  (# #p < 0.01;  # # #p < 0.001)  in  the  PROB-Form
subgroup  (black  triangles)  relative  to  the  Placebo-Form  subgroup.  There  was  no
significant difference between the findings on the Placebo-Phys and PROB-Phys animals
in any block. 
Fig. 2. Diagrams showing the rubbing activity in the first (A) and the second (B) phase in all
4 subgroups. In the Placebo group, the subcutaneous formalin injection (Placebo-Form)
induced a significant increase in rubbing activity in both the first and the second phase
(***p < 0.001) as compared with that  in the saline-treated  animals  (Placebo-Phys).  In
both phases, pre-treatment with PROB had a significant effect on mitigating the formalin-
induced increase in the time spent in rubbing (**p < 0.01; ***p < 0.001) as compared
with the Placebo-Form subgroup. 
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Fig. 3. (A) c-Fos-immunoreactive (IR) neurones (black arrow) in the superficial laminae of a
transverse section of medulla containing the caudal part of the spinal trigeminal nucleus
(TNC) in  the  Placebo-Form subgroup.  Subcutaneous formalin  injection  resulted  in  a
higher number of c-Fos-IR neurones on the ipsilateral side than on the contralateral side.
Scale  bar:  500 μm.  (B) c-Fos-IR neurones  on the formalin-treated  ipsilateral  sides  of
sections in the TNC in the two subgroups. The formalin-induced increase in IR cells was
more prominent on the ipsilateral side in the Placebo-Form subgroup (B/a) than in the
probenecid (PROB) (B/b)-pretreated animals. Scale bar: 200 μm. (C) Diagram showing
the mean number of c-Fos-IR cells  in the superficial  laminae of the TNC at different
levels along the rostrocaudal axis (mean ± S.E.M, n=9 per  subgroup). In the Placebo-
Form subgroup, formalin produced a significantly higher number of c-Fos-IR neurones
on  the  formalin-treated  side  of  the  TNC  as  compared  with  the  contralateral  side  at
different levels along the rostrocaudal axis (between -0.3 and -3.3 mm), in accordance
with  the  somatotopic  representation  (**p < 0.01;  ***p < 0.001).  PROB  pre-treatment
significantly  decreased  the  effect  of  formalin  between  -0.3  and  -2.4  mm  (#p < 0.05;
# #p < 0.01; # # #p < 0.001).
Fig. 4. (A) Immunostained transverse sections of medulla containing the caudal part of
the  spinal  trigeminal  nucleus  (TNC)  from  the  Placebo-Form  and  probenecid
(PROB)-Form  subgroup.  Black  arrow  shows  the  neuronal  nitric-oxide  synthase
(nNOS)-immunoreactive (IR) neurones in the superficial area of the TNC. On the
ipsilateral  side  (A/b),  more  nNOS-IR  neurones  can  be  observed  than  on  the
contralateral  side  (A/a)  in  the  Placebo-Form subgroup.  After  formalin  injection,
there  is  a  lower  number  of  nNOS-IR  neurones  on  the  ipsilateral  side  in  the
probenecid  (PROB)-Form  subgroup  (A/d)  than  in  the  Placebo-Form  subgroup
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(A/b). In these two subgroups, difference between the contralateral sides cannot be
observed. Scale bar: 200 μm. (B) Diagram showing the mean number of nNOS-IR
cells in the superficial area of the TNC at different levels along the rostrocaudal axis
(mean ± S.E.M, n=5 per subgroup).  Formalin produced a significant increase in
number  of  nNOS-IR  neurones  on  the  formalin-treated  side  of  the  TNC  in  the
Placebo-Form subgroup as compared with the contralateral side at different levels
along the rostrocaudal axis (between -2.1 and -2.7 and between -3.3 and -3.9 mm;
*p < 0.05; **p < 0.01).  The effect  of  formalin was significantly  decreased by pre-
treatment  with  PROB  between  -2.1  and  -2.7  and  between  -3.3  and  -3.9  mm
(#p < 0.05; # #p < 0.01). There was no significant difference between the contralateral
sides.
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